Skip to main content

Table 4 Dose dependent effects of irbesartan on metabolic parameters in patients with metabolic syndrome

From: Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study

Parameter

150 mg/da

300 mg/da

p-valueb

150 mg/d + HCTa

300 mg/d + HCTa

p-valuec

Glucose [mg/dl]

-9.1 ± 30.5

-12.3 ± 34.7

0.092

-7.8 ± 23.9

-14.3 ± 30.7

< 0.0001

HbA1c [%]

-0.24 ± 0.8

-0.30 ± 0.8

0.223

-0.26 ± 0.6

-0.34 ± 0.7

0.035

LDL-cholesterol [mg/dl]

-11.2 ± 26.92

-16.6 ± 30.4

0.004

-12.4 ± 26.4

-17.3 ± 33.3

0.001

HDL-cholesterol [mg/dl]

1 ± 37.4

2.8 ± 25.6

0.393

2.1 ± 22.6

4.1 ± 33.6

0.156

Triglycerides [mg/dl]

-27.4 ± 75.8

-31.0 ± 73.6

0.440

-30.9 ± 68.9

-40.3 ± 133.9

0.060

Gamma-GT [U/l]

-4.7 ± 37.2

-7.3 ± 24.2

0.257

-4.2 ± 21.7

-6.4 ± 32.4

0.142

Hs-CRP [mg/l]

-0.42 ± 2.9

-0.80 ± 10.5

0.704

-0.47 ± 1.4

-1.25 ± 7.2

0.111

  1. a absolute change; b relates to difference between irbesartan 150 mg/d and irbesartan 300 mg/d; c relates to difference between irbesartan 150 mg/d with HCT (12.5 mg/d) and irbesartan 300 mg/d with HCT (12.5 mg/d).